Atara Biotherapeutics Inc (ATRA) Given Average Rating of “Hold” by Brokerages
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have been assigned an average rating of “Hold” from the twelve research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $42.80.
A number of equities research analysts recently commented on ATRA shares. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd. Citigroup lowered their price objective on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research note on Monday, June 11th. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, August 3rd. Finally, BidaskClub cut shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th.
Shares of NASDAQ:ATRA traded down $0.20 on Wednesday, reaching $39.65. 13,573 shares of the company were exchanged, compared to its average volume of 578,642. Atara Biotherapeutics has a 1-year low of $12.65 and a 1-year high of $54.45. The stock has a market cap of $1.81 billion, a PE ratio of -9.91 and a beta of 2.54.
In other Atara Biotherapeutics news, EVP Christopher Haqq sold 775 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $37.54, for a total value of $29,093.50. Following the transaction, the executive vice president now directly owns 331,355 shares in the company, valued at approximately $12,439,066.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction dated Tuesday, June 26th. The shares were sold at an average price of $40.31, for a total transaction of $177,364.00. Following the completion of the transaction, the chief executive officer now owns 812,613 shares in the company, valued at $32,756,430.03. The disclosure for this sale can be found here. Over the last three months, insiders sold 115,575 shares of company stock worth $4,505,531. 10.60% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can lifted its holdings in Atara Biotherapeutics by 100.1% in the 2nd quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 1,655 shares in the last quarter. United Services Automobile Association lifted its holdings in Atara Biotherapeutics by 28.4% in the 2nd quarter. United Services Automobile Association now owns 8,132 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 1,797 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Atara Biotherapeutics by 14.1% in the 2nd quarter. Voya Investment Management LLC now owns 16,022 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 1,979 shares in the last quarter. TD Asset Management Inc. lifted its holdings in Atara Biotherapeutics by 4.9% in the 2nd quarter. TD Asset Management Inc. now owns 43,089 shares of the biotechnology company’s stock valued at $1,584,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Riverhead Capital Management LLC purchased a new position in Atara Biotherapeutics in the 1st quarter valued at about $100,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: Do stock splits help investors?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.